CCM Biosciences

CCM Biosciences is a biotechnology company dedicated to the discovery and development of novel drugs, including small molecules, gene therapies, biologics, and nanomedicines. The innovative therapeutic candidates and companion diagnostic tests aim to address various indications in precision oncology, rare diseases, autoimmune disorders, and age-related conditions. CCM Biosciences boasts a broad portfolio of novel candidates, including KRAS-disrupting therapies targeting oncogenes responsible for 25% of cancers, first-in-class selective degraders of oncogenic kinases for lung cancer and leukemia, cGAS inhibitors as immunomodulators for autoimmune diseases, therapies addressing nonsense mutations which account for 10% of all genetic disorders, and disruptive candidates modulating mitochondrial upregulation associated with a range of age-related diseases such as Parkinson’s disease, Alzheimer’s disease, and infertility.